Abstract: An improved method for the preparation of the low ABUK oxymorphone hydrochloride is provided. The oxymorphone hydrochloride is produced by hydrogenating a starting material comprising oxymorphone base and 14-hydroxymorphinone in a mixture comprising an alcohol, water and an acid, removing some of the water and adding more alcohol to the mixture.

Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.

Abstract: The invention relates to methods of separating Trolox isomers (R)-Trolox and (S)-Trolox, comprising: (a) contacting a mixture of (R) and (S)-Trolox with a resolving agent selected from the group consisting of (1S,2S)-(+)-Pseudoephedrine, (R)-(+)-2-Amino-3-phenyl-1-propanol, (1R,2R)-(?)-Pseudoephedrine, and (S)-(?)-2-Amino-3-phenyl-1-propanol, wherein the resolving agent forms a solid salt with one of (R)-Trolox and (S)-Trolox, and substantially does not form a solid salt with the other; and (b) separating the solid salt from the Trolox isomer that did not form the solid salt with the resolving agent.

Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.

Abstract: The present invention provides methods for obtaining purified rapamycin derivatives, including purified Biolimus A9. A crystalline form of Biolimus A9 is also described.

Abstract: The present invention provides methods for obtaining purified rapamycin derivatives, including purified Biolimus A9. A crystalline form of Biolimus A9 is also described.

Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.

Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.

Abstract: An improved method for the preparation of the low ABUK oxymorphone hydrochloride is provided. The oxymorphone hydrochloride is produced by hydrogenating a starting material comprising oxymorphone base and 14-hydroxymorphinone in a mixture comprising an alcohol, water and an acid, removing some of the water and adding more alcohol to the mixture.

Abstract: The present disclosure is directed to novel crystalline forms of silodosin and compositions comprising any of the novel crystalline forms of silodosin. Also provided are processes for the preparation of novel crystalline forms of silodosin.

Abstract: The present invention provides methods for obtaining purified rapamycin derivatives, including purified Biolimus A9. A crystalline form of Biolimus A9 is also described.

Abstract: The present disclosure is directed to crystalline forms of oxymorphone hydrochloride and compositions comprising any of the crystalline forms of oxymorphone hydrochloride. Also provided are processes for the preparation of crystalline forms of oxymorphone hydrochloride.

Abstract: In a computer network system, a command line interface system is described having a text-based browser for browsing details of host devices coupled to the network. The command line interface system data includes logic to monitor and manage network devices by allowing a user to traverse the network using text-based commands to view hierarchy and topology information of the network and the hosts. The command line interface browsing system advantageously ensures a command status state change in one hierarchy level of the host device being browsed is retained and communicated to other hierarchy levels as the user browses the network.

Abstract: In a computer network system, a command line interface system is described having a text-based browser for browsing details of host devices coupled to the network. The command line interface system data includes logic to monitor and manage network devices by allowing a user to traverse the network using text-based commands to view hierarchy and topology information of the network and the hosts. The command line interface browsing system advantageously ensures a command status state change in one hierarchy level of the host device being browsed is retained and communicated to other hierarchy levels as the user browses the network.